Tags:Development
DeuterOncology is focused on the pre-clinical validation and development of DO-2, a novel MET and RAS pathway inhibitor sublicensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017. DeuterOncology’s portfolio contains a sublicense to the all OCTIMET compounds, includes a clinical-stage MET kinase inhibitor that has been evaluated in both a monotherapy and combination therapy setting in cancer patients in Europe. DeuterOncology works together with a broad established network of collaborators across the world to try to bring new solutions to cancer patients
Member count: 1-10
Total raised: $6.118552M
Founded date: 2020

Investors 1

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
19.01.2023Series A$6.118552M-finsmes.co...

Mentions in press and media 2

DateTitleDescriptionCategoryAuthorSource
19.01.2023DeuterOnco...DeuterOncology, a Liege, Belgi...Belgium-finsmes.co...
-DeuterOnco...“Home | DeuterOncology NV”--fastfounde...